{"id":"background-pah-therapy","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a descriptive term for established PAH therapies used as a baseline or comparator in clinical trials, rather than a single novel drug entity. Background PAH therapy generally includes agents such as phosphodiesterase-5 inhibitors, endothelin receptor antagonists, or prostanoid analogs that work through different mechanisms to dilate pulmonary vessels and reduce right ventricular afterload.","oneSentence":"Background PAH Therapy refers to foundational pulmonary arterial hypertension treatment, typically involving vasodilators and/or endothelin receptor antagonists to reduce pulmonary vascular resistance.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:03:33.692Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pulmonary arterial hypertension (PAH)"}]},"trialDetails":[{"nctId":"NCT07218029","phase":"PHASE3","title":"A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-05-12","conditions":"Pulmonary Arterial Hypertension","enrollment":815},{"nctId":"NCT06554301","phase":"PHASE1","title":"A Study on the Efficacy and Safety of Empagliflozin in the Treatment of Pulmonary Arterial Hypertension","status":"RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2024-10-20","conditions":"Pulmonary Arterial Hypertension","enrollment":72},{"nctId":"NCT06120140","phase":"PHASE2","title":"Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-02-16","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":300},{"nctId":"NCT03626688","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients","status":"COMPLETED","sponsor":"United Therapeutics","startDate":"2018-08-30","conditions":"PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension","enrollment":687},{"nctId":"NCT05818137","phase":"PHASE3","title":"A Study of Sotatercept in Japanese Pulmonary Arterial Hypertension (PAH) Participants (MK-7962-020)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-05-10","conditions":"Pulmonary Arterial Hypertension","enrollment":46},{"nctId":"NCT04896008","phase":"PHASE3","title":"A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)","status":"COMPLETED","sponsor":"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA","startDate":"2021-12-01","conditions":"Pulmonary Arterial Hypertension","enrollment":173},{"nctId":"NCT07351773","phase":"NA","title":"Ultrasound-Guided Stellate Ganglion Block for Alzheimer's Disease","status":"COMPLETED","sponsor":"Taizhou Second People's Hospital","startDate":"2025-01-26","conditions":"Alzheimer's Disease(AD), Cognitive Dysfunction","enrollment":40},{"nctId":"NCT07356778","phase":"PHASE4","title":"A Study of Sotatercept for Patients With Eisenmenger Syndrome or Unrepaired Shunt-Associated Pulmonary Arterial Hypertension Resistant to Vasodilator Therapy","status":"RECRUITING","sponsor":"Kazuya Hosokawa","startDate":"2025-10-07","conditions":"Eisenmenger Syndrome, Pulmonary Arterial Hypertension of Congenital Heart Disease","enrollment":36},{"nctId":"NCT06664801","phase":"PHASE2","title":"A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-11-14","conditions":"Pulmonary Arterial Hypertension","enrollment":164},{"nctId":"NCT06925750","phase":"PHASE2","title":"A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-05-12","conditions":"Pulmonary Arterial Hypertension","enrollment":130},{"nctId":"NCT07229495","phase":"PHASE4","title":"Tegileridine for Postoperative Pain After Adolescent Scoliosis Surgery","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2026-01-01","conditions":"Scoliosis; Adolescence, Pain After Surgery, Analgesia, Patient-controlled","enrollment":171},{"nctId":"NCT05975905","phase":"PHASE2","title":"A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS Study).","status":"COMPLETED","sponsor":"Keros Therapeutics, Inc.","startDate":"2023-10-17","conditions":"Pulmonary Arterial Hypertension","enrollment":113},{"nctId":"NCT07177703","phase":"PHASE2","title":"Efficacy and Safety of Treprostinil in Intermediate-Risk Pulmonary Arterial Hypertension","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-10-31","conditions":"Pulmonary Arterial Hypertension (PAH)","enrollment":32},{"nctId":"NCT00712712","phase":"PHASE2","title":"Morphine After Radiofrequency Ablation of Painful Bone Metastases in Patients With Cancer","status":"COMPLETED","sponsor":"Institut Bergonié","startDate":"2007-12-24","conditions":"Metastatic Cancer, Pain, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":78},{"nctId":"NCT07143448","phase":"PHASE1","title":"A Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in Adults","status":"NOT_YET_RECRUITING","sponsor":"35Pharma Inc","startDate":"2025-10","conditions":"Pulmonary Arterial Hypertension","enrollment":40},{"nctId":"NCT06493461","phase":"PHASE1","title":"A Study of HS135 for the Treatment of Pulmonary Arterial Hypertension in Adults","status":"TERMINATED","sponsor":"35Pharma Inc","startDate":"2024-10-23","conditions":"Pulmonary Arterial Hypertension (PAH)","enrollment":5},{"nctId":"NCT01974440","phase":"PHASE3","title":"A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-01-31","conditions":"Lymphoma","enrollment":403},{"nctId":"NCT04785768","phase":"PHASE3","title":"IV PCA With or Without Continuous Dose vs Oral Opioid to Maintain Analgesia for Severe Cancer Pain After Successful Titration","status":"COMPLETED","sponsor":"Fujian Cancer Hospital","startDate":"2021-07-01","conditions":"Cancer Pain","enrollment":1372},{"nctId":"NCT04811092","phase":"PHASE3","title":"Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13)","status":"COMPLETED","sponsor":"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA","startDate":"2022-03-18","conditions":"Pulmonary Arterial Hypertension","enrollment":321},{"nctId":"NCT06949852","phase":"PHASE3","title":"Evaluation of Safety and Efficacy of Nalbuphine Versus Morphine for Postoperative Analgesia","status":"RECRUITING","sponsor":"Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd","startDate":"2024-08-07","conditions":"Postoperative Analgesia","enrollment":288},{"nctId":"NCT05339386","phase":"","title":"Developing Hyperpolarized 129Xe MRI Biomarkers for Evaluation of Pulmonary Arterial Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Kansas Medical Center","startDate":"2022-08-29","conditions":"Pulmonary Arterial Hypertension","enrollment":10},{"nctId":"NCT06897917","phase":"PHASE4","title":"Real World Study of Oxycodone/Naloxone Sustained-Release Tablets (Mimeixin) for Patients With Severe Cancer Pain","status":"NOT_YET_RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2025-04","conditions":"Opioid-Induced Constipation, Pain Cancer","enrollment":203},{"nctId":"NCT04231448","phase":"PHASE3","title":"Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chipscreen Biosciences, Ltd.","startDate":"2020-05-21","conditions":"Diffuse Large B-cell Lymphoma","enrollment":423},{"nctId":"NCT06411665","phase":"PHASE4","title":"Effect of Oliceridine Analgesia on Postoperative Nause and Vomiting","status":"RECRUITING","sponsor":"Peking University First Hospital","startDate":"2024-07-02","conditions":"Postoperative Nausea and Vomiting","enrollment":252},{"nctId":"NCT04576988","phase":"PHASE3","title":"A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR)","status":"COMPLETED","sponsor":"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA","startDate":"2021-01-25","conditions":"Pulmonary Arterial Hypertension","enrollment":324},{"nctId":"NCT06317805","phase":"PHASE4","title":"Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients","status":"RECRUITING","sponsor":"AOP Orphan Pharmaceuticals AG","startDate":"2023-12-06","conditions":"Pulmonary Arterial Hypertension","enrollment":110},{"nctId":"NCT05930912","phase":"","title":"Psychiatric Orders in Psychoanalytic Treatment of ASD","status":"UNKNOWN","sponsor":"Yang I. Pachankis, PhD","startDate":"2023-06-01","conditions":"PTSD, Autism Spectrum Disorder High-Functioning, OCD","enrollment":1},{"nctId":"NCT03835676","phase":"PHASE4","title":"Effects of Treprostinil on Right Ventricular Structure and Function in Patients With Pulmonary Arterial Hypertension","status":"UNKNOWN","sponsor":"Magdi H. Yacoub","startDate":"2019-05-01","conditions":"Pulmonary Hypertension","enrollment":30},{"nctId":"NCT02703272","phase":"PHASE3","title":"A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2016-07-01","conditions":"Lymphoma, Non-Hodgkin","enrollment":72},{"nctId":"NCT05463809","phase":"PHASE3","title":"Compare Continuous Gastrocnemius Plane Block With Intravenous Analgesia After Foot and Ankle Surgery","status":"UNKNOWN","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2022-07-14","conditions":"Foot Ankle Injuries","enrollment":60},{"nctId":"NCT04053543","phase":"PHASE2","title":"CXA-10 Study in Subjects With Pulmonary Arterial Hypertension","status":"TERMINATED","sponsor":"Complexa, Inc.","startDate":"2019-08-09","conditions":"PAH","enrollment":33},{"nctId":"NCT03449524","phase":"PHASE2","title":"PRIMEx - A Study of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH)","status":"TERMINATED","sponsor":"Complexa, Inc.","startDate":"2018-08-01","conditions":"PAH","enrollment":69},{"nctId":"NCT03176121","phase":"PHASE4","title":"Study Evaluating Safety and Tolerability of Oxycodone in Patients With Moderate to Severe Cancer Pain","status":"COMPLETED","sponsor":"Taiwan Mundipharma Pharmaceuticals Ltd.","startDate":"2016-10-31","conditions":"Cancer, Pain","enrollment":73},{"nctId":"NCT03275012","phase":"PHASE2","title":"Efficacy and Safety Study of Gabapentin as add-on to Morphine in Paediatric Patients Affected by Chronic Pain","status":"WITHDRAWN","sponsor":"Pharmaceutical Research Management srl","startDate":"2017-04-04","conditions":"Chronic Pain","enrollment":""},{"nctId":"NCT02869321","phase":"PHASE4","title":"Analgesic Efficacy of Transmucosal Fentanyl for Breakthrough Pain Caused by Interventional Gastrostomy","status":"COMPLETED","sponsor":"Central Hospital, Nancy, France","startDate":"2015-05","conditions":"Gastrostomy, Breakthrough Pain, Upper Aerodigestive Tract Neoplasms","enrollment":20},{"nctId":"NCT01712009","phase":"PHASE2","title":"NOLAN: Naproxen or Loratadine and Neulasta","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-11-01","conditions":"Bone Pain in Stage I - III Breast Cancer","enrollment":600},{"nctId":"NCT01677754","phase":"PHASE2","title":"A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-10-24","conditions":"Alzheimer's Disease","enrollment":542},{"nctId":"NCT01179334","phase":"PHASE2","title":"Evaluation of the Pharmacodynamic Effect of the Combination of Sildenafil and Riociguat on Blood Pressure and Other Safety Parameters.","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-08","conditions":"Pulmonary Hypertension","enrollment":18},{"nctId":"NCT01426880","phase":"PHASE2, PHASE3","title":"Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2011-08","conditions":"Tubular Breast Cancer Stage II, Mucinous Breast Cancer Stage II, Breast Cancer Female NOS","enrollment":595},{"nctId":"NCT01304134","phase":"PHASE3","title":"Oxycodone Hydrochloride Injection in the Postoperative Pain Relieving Treatment","status":"COMPLETED","sponsor":"Mundipharma (China) Pharmaceutical Co. Ltd","startDate":"2010-03","conditions":"Other Acute Postoperative Pain","enrollment":240},{"nctId":"NCT00461630","phase":"PHASE3","title":"Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2007-01","conditions":"Cardiovascular Disease, Peripheral Arterial Disease, Diabetes Mellitus","enrollment":25673},{"nctId":"NCT00984750","phase":"PHASE3","title":"Acetyl-L-Carnitine in Type 2 Diabetes","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2008-04","conditions":"Diabetes Type 2, Hypertension","enrollment":229},{"nctId":"NCT00617305","phase":"PHASE4","title":"Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2008-04","conditions":"Pulmonary Arterial Hypertension","enrollment":38},{"nctId":"NCT01518192","phase":"PHASE4","title":"Comparison of Doxycycline and Cefuroxime Axetil for Treatment of Erythema Migrans: Clinical and Microbiological Outcome","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2006-06","conditions":"Erythema Migrans, Post-Lyme Disease Symptoms","enrollment":544},{"nctId":"NCT00702416","phase":"PHASE4","title":"Ultrasound Guidance for Interscalene Brachial Plexus Block","status":"COMPLETED","sponsor":"University of Parma","startDate":"2008-05","conditions":"Shoulder, Orthopedic Surgery, Nerve Block","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":15,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Background PAH Therapy","genericName":"Background PAH Therapy","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Biologic","firstApprovalDate":"","aiSummary":"Background PAH Therapy refers to foundational pulmonary arterial hypertension treatment, typically involving vasodilators and/or endothelin receptor antagonists to reduce pulmonary vascular resistance. Used for Pulmonary arterial hypertension (PAH).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}